Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05253807
Title Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration (FIGHT-210)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Incyte Corporation
Indications

lung non-small cell carcinoma

Therapies

Pemigatinib

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU

Additional content available in CKB BOOST